SMi's inaugural Cancer Vaccines conference - 19th & 20th September 2012 London
Novel strategies to improve success in cancer vaccines clinical trials
There have so far only been three cancer vaccines approved by the FDA, and many others are now nearing the end of their clinical trials. Two of these were vaccines for HPV, which is responsible for 70% of cervical cancer. The most recent, and most exciting is the approval of Provenge last year, which is a vaccine for Prostate Cancer by Dendreon.
With a successful pathway through the commercialization and regulatory process now mapped out, companies are really starting to increase their work in this field to ensure success in clinical trials.
SMi's inaugural conference on Cancer Vaccines will provide attendees with a complete view of the cancer immunotherapy field, focusing on the discovery of new vaccines, developments in target identification and vaccine delivery strategies, this informative event will bring together key opinion leaders in the field to provide attendees with an in depth look into current advances in cancer vaccines.
Key benefits of attending
Consider novel combination therapies in cancer vaccine development
Understand effective process development strategies
Evaluate developments in cell based immunotherapeutics
Discover strategies to improve success and overcome current issues in clinical trials
Learn about clinical and regulatory design of immunotherapy programs
Hear from the industry on updates on the most recent successful candidates in Phase III
Develop monitoring immunotherapy outcomes
Network and learn from key opinion leaders from industry and academia
For more information visit http://www.smi-